Testing pacritinib for VEXAS syndrome
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed UBA1 gene mutation (the one that causes VEXAS syndrome).
- You must have had at least one VEXAS symptom in the past or present, such as a rash, joint pain, fever, or low blood counts.
- You can have tried a JAK inhibitor before, but if you did, it must not have worked well enough, and you need to stop it for at least 28 days before starting this trial.
- Your steroid dose (like prednisone) must be stable for at least 14 days before you start the study drug.
- You must be 18 or older and have adequate organ function (kidneys, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug pacritinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition that causes inflammation in various parts of the body. It may be a new treatment option for those who still have inflammation despite taking steroids.
This study tests whether the drug momelotinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition. Participants will keep taking their usual steroids and may receive momelotinib or a placebo to see if it helps control the disease.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This study aims to find out how common VEXAS syndrome is and how it looks in people over 50 who have unexplained inflammation or blood issues. It helps doctors better recognize and diagnose this rare condition.
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Hear when a new VEXAS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.